MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10742484221146375

Медицинская библиотека · Journal of cardiovascular pharmacology and therapeutics · 2023

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction.

Matsumura Koichiro, Ijichi Takeshi, Morimoto Junko, Takabayashi Kensuke, Miho Mitsunori, Ueno Keisuke, Yagi Eijiro, Takase Toru, Ueno Masafumi, Nakazawa Gaku

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

AIMS: In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients with HF. However, many patients do not achieve the target dose of treatment. This study investigated the factors linked to up-titration of sacubitril/valsartan in patients with heart failure and preserved ejection fraction (HFpEF).

METHODS

Using a multicenter retrospective database, 204 consecutive patients with HFpEF (left ventricular ejection fraction ≥ 40%) who were treated with sacubitril/valsartan between October 2020 and March 2022 were analyzed. Up-titration was defined as an increase in dosage above 24/26 mg BID beyond 12 weeks after the initiation of sacubitril/valsartan.

RESULTS

Among the patients, 55% underwent up-titration, and 8% discontinued the drug. The baseline systolic blood pressure (SBP) was higher in patients with up-titration than in those with no up-titration; SBP values similar to that at baseline were observed between the 2 groups at 2 to 4 weeks and at 12 weeks after the commencement of sacubitril/valsartan treatment. The majority of those who discontinued sacubitril/valsartan did so because of hypotension. The multivariable logistic regression model showed that a history of hypertension, history of atrial fibrillation, baseline SBP, and baseline estimated glomerular filtration rate <60 mL/min/1.73 m2 were associated with sacubitril/valsartan up-titration.

CONCLUSION

Approximately half of all patients did not undergo up-titration, and 8% of those with HFpEF discontinued the sacubitril/valsartan therapy. For aggressive up-titration and continuation of sacubitril/valsartan, patients with lower baseline SBP, renal dysfunction, absence of a history of hypertension, and presence of atrial fibrillation may require more careful monitoring.

Для цитирования: Matsumura Koichiro, Ijichi Takeshi, Morimoto Junko, Takabayashi Kensuke, Miho Mitsunori, Ueno Keisuke, Yagi Eijiro, Takase Toru, Ueno Masafumi, Nakazawa Gaku. Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction.. Journal of cardiovascular pharmacology and therapeutics. 2023. DOI: 10.1177/10742484221146375.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.